Skip to Main Content

A biotech company that hoped to use cell biology to address neurological disorders is shutting down.

Faze Medicines was built by VC Third Rock Ventures and launched in 2020 with $81 million from Third Rock, Casdin Capital, and venture funds run by drug giants Novartis, Eli Lilly, and AbbVie.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment